EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
2021 · Scientific Reports · 40 citations
https://doi.org/10.1038/s41598-021-00889-0
M
Motohiko Oshima
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
86
Papers
949
Citations
15
h-index
19
i10-index
Motohiko Oshima is an academic researcher from The University of Tokyo. The author has contributed to research in topics: Epigenetics and DNA Methylation & Acute Myeloid Leukemia Research & Multiple Myeloma Research and Treatments. The author has an h-index of 15, co-authored 74 publications.
ORCID: 0000-0001-6991-815XPapers by this author
worksSUMO Modification Regulates the Transcriptional Repressor Function of Aryl Hydrocarbon Receptor Repressor
2009 · Journal of Biological Chemistry · 37 citations
https://doi.org/10.1074/jbc.m808694200
Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs
2021 · Stem Cell Reports · 15 citations
https://doi.org/10.1016/j.stemcr.2021.11.001
Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model
2024 · Nature Communications · 14 citations
https://doi.org/10.1038/s41467-024-48663-w
UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease
2023 · Leukemia · 4 citations
https://doi.org/10.1038/s41375-023-01928-7
Long-term radiation effects on human HSPCs in primary recipient mice.
2015 · Figshare · 0 citations
https://doi.org/10.1371/journal.pone.0132041.g004
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat